Targeting the HIV reservoir:chimeric antigen receptor therapy for HIV cure

作     者：Shuang Li Hu Wang Na Guo Bin Su Olivier Lambotte Tong Zhang 

作者机构：Beijing Key Laboratory for HIV/AIDS ResearchSino-French Joint Laboratory for Research on Humoral Immune Response to HIV InfectionClinical and Research Center for Infectious DiseasesBeijing Youan HospitalCapital Medical UniversityBeijing 100069China Department of Internal MedicineAP-HPBicêtre HospitalUMR1184 INSERM CEALe Kremlin BicêtreUniversity Paris SaclayParis 94270France 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第22期

页      面：2658-2667页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by grants from the National Key R&D Program of China(Nos.2021YFC2301900 and 2021YFC2301905) the National Natural Science Foundation of China(Nos.NSFC,81974303 and 82072271) Beijing Natural Science Foundation(Nos.L222068 and Z220018) the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission(Nos.2022-2-018 and 2022-1-007) the Climbing the peak(Dengfeng)Talent Training Program of Beijing Hospitals Authority(Nos.DFL20191701) the Beijing Health Technologies Promotion Program(BHTPP202002)and Beijing Key Laboratory for HIV/AIDS Research(No.BZ0089) 

主　　题：Functional HIV cure HIV reservoir Chimeric antigen receptor therapy CAR T cells CAR natural killer cells 

摘      要：Although antiretroviral therapy(ART)can reduce the viral load in the plasma to undetectable levels in human immunodeficiency virus(HIV)-infected individuals,ART alone cannot completely eliminate HIV due to its integration into the host cell genome to form viral *** achieve a functional cure for HIV infection,numerous preclinical and clinical studies are underway to develop innovative immunotherapies to eliminate HIV reservoirs in the absence of *** studies have tested adoptive T-cell therapies in HIV-infected individuals,but their effectiveness was *** recent years,with the technological progress and great success of chimeric antigen receptor(CAR)therapy in the treatment of hematological malignancies,CAR therapy has gradually shown its advantages in the field of HIV *** studies have identified a variety of HIV-specific CAR structures and types of cytolytic effector ***,CAR therapy may be beneficial for enhancing HIV immunity,achieving HIV control,and eliminating HIV reservoirs,gradually becoming a promising strategy for achieving a functional HIV *** this review,we provide an overview of the design of anti-HIV CAR proteins,the cell types of anti-HIV CAR(including CAR T cells,CAR natural killer cells,and CAR-encoding hematopoietic stem/progenitor cells),the clinical application of CAR therapy in HIV infection,and the prospects and challenges in anti-HIV CAR therapy for maintaining viral suppression and eliminating HIV reservoirs.